Literature DB >> 27885264

Deciphering the divergent roles of progestogens in breast cancer.

Jason S Carroll1, Theresa E Hickey2, Gerard A Tarulli2, Michael Williams3, Wayne D Tilley2.   

Abstract

Most breast cancers are driven by oestrogen receptor-α. Anti-oestrogenic drugs are the standard treatment for these breast cancers; however, treatment resistance is common, necessitating new therapeutic strategies. Recent preclinical and historical clinical studies support the use of progestogens to activate the progesterone receptor (PR) in breast cancers. However, widespread controversy exists regarding the role of progestogens in this disease, hindering the clinical implementation of PR-targeted therapies. Herein, we present and discuss data at the root of this controversy and clarify the confusion and misinterpretations that have consequently arisen. We then present our view on how progestogens may be safely and effectively used in treating breast cancer.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27885264     DOI： 10.1038/nrc.2016.116

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  168 in total

Review 1.  Clinical use of oestrogens and progestogens.

Authors:  C Lauritzen
Journal:  Maturitas       Date:  1990-09       Impact factor: 4.342

2.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

3.  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

Authors:  A Buzdar; J Douma; N Davidson; R Elledge; M Morgan; R Smith; L Porter; J Nabholtz; X Xiang; C Brady
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

4.  Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels.

Authors:  P Bonomi; P Johnson; K Anderson; J Wolter; N Bunting; A Strauss; D Roseman; W Shorey; S Economou
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

5.  Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors.

Authors:  M Stierer; H Rosen; R Weber; H Hanak; J Spona; H Tüchler
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

Review 6.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

7.  Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.

Authors:  Amelia A Peters; Grant Buchanan; Carmela Ricciardelli; Tina Bianco-Miotto; Margaret M Centenera; Jonathan M Harris; Shalini Jindal; Davendra Segara; Li Jia; Nicole L Moore; Susan M Henshall; Stephen N Birrell; Gerhard A Coetzee; Robert L Sutherland; Lisa M Butler; Wayne D Tilley
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

8.  Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases.

Authors:  J Alexieva-Figusch; H A van Gilse; W C Hop; C H Phoa; J Blonk-van der Wijst; R E Treurniet
Journal:  Cancer       Date:  1980-12-01       Impact factor: 6.860

9.  The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone.

Authors:  I J Laidlaw; R B Clarke; A Howell; A W Owen; C S Potten; E Anderson
Journal:  Endocrinology       Date:  1995-01       Impact factor: 4.736

Review 10.  Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.

Authors:  Noor Asi; Khaled Mohammed; Qusay Haydour; Michael R Gionfriddo; Oscar L Morey Vargas; Larry J Prokop; Stephanie S Faubion; Mohammad Hassan Murad
Journal:  Syst Rev       Date:  2016-07-26
View more
  46 in total

1.  The Flavonoid Apigenin Is a Progesterone Receptor Modulator with In Vivo Activity in the Uterus.

Authors:  Matthew Dean; Julia Austin; Ren Jinhong; Michael E Johnson; Daniel D Lantvit; Joanna E Burdette
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

2.  Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer.

Authors:  Merit L Goodman; Gloria M Trinca; Katherine R Walter; Evangelia K Papachristou; Clive S D'Santos; Tianbao Li; Qi Liu; Zhao Lai; Prabhakar Chalise; Rashna Madan; Fang Fan; Mary A Markiewicz; Victor X Jin; Jason S Carroll; Christy R Hagan
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

3.  Phospho-PR Isoforms and Cancer Stem Cells: What Does the FOXO1 Say?

Authors:  Lynsey M Fettig; Carol A Sartorius
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

Review 4.  Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.

Authors:  Viroj Boonyaratanakornkit; Nalo Hamilton; Diana C Márquez-Garbán; Prangwan Pateetin; Eileen M McGowan; Richard J Pietras
Journal:  Mol Cell Endocrinol       Date:  2017-11-14       Impact factor: 4.102

5.  Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

Authors:  Yiyang Li; Cheng Huang; Tamar Kavlashvili; Abby Fronk; Yuping Zhang; Yang Wei; Donghai Dai; Eric J Devor; Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie; Shujie Yang
Journal:  Am J Cancer Res       Date:  2020-06-01       Impact factor: 6.166

Review 6.  O-GlcNAcylation in women's cancers: breast, endometrial and ovarian.

Authors:  Gloria M Trinca; Christy R Hagan
Journal:  J Bioenerg Biomembr       Date:  2017-11-10       Impact factor: 2.945

7.  O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer.

Authors:  Gloria M Trinca; Merit L Goodman; Evangelia K Papachristou; Clive S D'Santos; Prabhakar Chalise; Rashna Madan; Chad Slawson; Christy R Hagan
Journal:  Horm Cancer       Date:  2017-09-19       Impact factor: 3.869

8.  Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer.

Authors:  Katherine R Walter; Merit L Goodman; Hari Singhal; Jade A Hall; Tianbao Li; Sean M Holloran; Gloria M Trinca; Katelin A Gibson; Victor X Jin; Geoffrey L Greene; Christy R Hagan
Journal:  Mol Cancer Res       Date:  2017-07-06       Impact factor: 5.852

9.  Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.

Authors:  Jessica Finlay-Schultz; Austin E Gillen; Heather M Brechbuhl; Joshua J Ivie; Shawna B Matthews; Britta M Jacobsen; David L Bentley; Peter Kabos; Carol A Sartorius
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

10.  Baicalein Is a Phytohormone that Signals Through the Progesterone and Glucocorticoid Receptors.

Authors:  Julia R Austin; Brenna J Kirkpatrick; Rocío Rivera Rodríguez; Michael E Johnson; Daniel D Lantvit; Joanna E Burdette
Journal:  Horm Cancer       Date:  2020-03-07       Impact factor: 3.869
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.